Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: nonmelanoma skin cancer

Methotrexate Increases Risk of Recurrent Nonmelanoma Skin Cancer

Will Boggs, MD  |  November 4, 2015

NEW YORK (Reuters Health)—Methotrexate appears to increase the risk of recurrent nonmelanoma skin cancer (NMSC) in patients with rheumatoid arthritis (RA), according to a retrospective study. “We have known for some time that several of the immunosuppressive agents used to treat RA and inflammatory bowel disease (IBD) are also associated with an increased risk of…

Filed under:Drug Updates Tagged with:Cancerinflammatory bowel diseaseMethotrexatenonmelanoma skin cancer (NMSC)Rheumatiod arthritis

Cancer cells

Cancer & RA Drugs: Are Some Drugs Riskier than Others?

Samantha C. Shapiro, MD  |  February 4, 2025

Sendaydiego et al. asked: Do some DMARDs pose a greater cancer risk than others for patients with RA? Here are insights from the study and its clinical implications.

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis

IBD Treatments Don’t Seem to Raise Extracolonic Cancer Risk

Reuters Staff  |  June 8, 2017

NEW YORK (Reuters Health)—Immunosuppressants and anti-TNF drugs do not appear to increase the risk of extracolonic cancers in patients with inflammatory bowel disease (IBD), researchers from Spain report. IBD patients face an increased risk of colon cancer, and some studies have suggested there might be an increased risk of extracolonic cancer. Dr. Maria Chaparro from…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:Anti-TNFanti-TNF agentCancerIBDinflammatory bowel diseasenonmelanoma skin cancer (NMSC)

Cancer Risk for Patients with Juvenile Idiopathic Arthritis Taking TNF Inhibitors

Thomas R. Collins  |  March 20, 2017

WASHINGTON, D.C.—Juvenile idiopathic arthritis (JIA) patients taking TNF inhibitors don’t develop new cancers at a higher rate than JIA patients who don’t take TNF inhibitors, according to the largest study so far conducted to study the possible link. The findings were reported at the 2016 ACR/ARHP Annual Meeting in an abstract session that also included…

Filed under:ConditionsMeeting ReportsResearch Rheum Tagged with:2016 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)CancerinhibitorJuvenile idiopathic arthritisPediatricsrateResearchrheumatologyriskTNFTreatment

Does Methotrexate Increase Skin Cancer Risk?

Lara C. Pullen, PhD  |  November 16, 2015

A recent study connects the use of immunosuppressant and biologic agents to an increased risk of nonmelanoma skin cancer in patients being treated for RA and IBD…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Cancerinflammatory bowel diseaseMethotrexatenonmelanoma skin cancer (NMSC)Rheumatoid Arthritis (RA)rituximab

2014 ACR/ARHP Annual Meeting: Autoimmune Connective Tissue Diseases and Cancer

Susan Bernstein  |  April 1, 2015

Links between autoimmunity, malignancy prompt rheumatologists to include cancer screening for patients

Filed under:Meeting Reports Tagged with:ACR/ARHP Annual MeetingAutoimmuneBernsteinCancerconnective tissue diseasemalignancypatient carerheumatologyscreening

15,000 Patient-Years: Safety Data for Upadacitinib Treatment Across Multiple Rheumatic Conditions

Michele B. Kaufman, PharmD, BCGP  |  October 17, 2024

Burmester et al. characterized the long-term safety profile of upadacitinib treatment across multiple rheumatic diseases.

Filed under:Biologics/DMARDsConditionsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:EULAREULAR 2024Safetyupadacitinib

Psoriatic Arthritis: Advances in Therapeutics, Imaging & More Presented at ACR Convergence 2022

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  December 1, 2022

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…

Filed under:ACR ConvergenceAxial SpondyloarthritisConditionsMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2022ACR Convergence 2022 – PsAPsoriatic Arthritis

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

Keri Losavio  |  September 1, 2021

On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…

Filed under:Drug Updates Tagged with:baricitinibJAK inhibitorsjakinibsTofacitinibupadacitinib

MicroOne / shutterstock.com

Rheumatology Drugs at a Glance, Part 2: Psoriasis

Mary Choy, PharmD, BCGP, FASHP  |  May 17, 2019

Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:ConditionsDrug Updates Tagged with:adalimumabapremilastbrodalumabCertolizumab Pegoletanerceptguselkumabguttate psoriasisinfliximabinverse psoriasisixekizumabPsoriatic Arthritispsoriatic erythrodermapustular psoriasisRheumatic Drugs at a Glancesecukinumabtildrakizumabustekinumabvulgar psoriasis

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences